RAILY AESMED (Raily Aesthetic Medicine International Holdings Limited) reported a return to profitability for the six months ended 30 June 2026, posting net profit of RMB3.50 million versus a RMB9.46 million loss a year earlier. Profit attributable to shareholders reached RMB4.10 million, compared with a RMB7.57 million loss in 1H25.

Revenue climbed 35.7% year-on-year to RMB114.78 million. The group’s aesthetic medical services segment contributed RMB78.28 million, up 4.5%, while sales of aesthetic medical device products soared 289.9% to RMB36.50 million, driven primarily by collagen filler Bellafill. Bellafill generated RMB36.20 million in revenue, a 302.2% increase, with registered medical institutions expanding to approximately 450 and certified physicians to about 740.

Gross profit rose 51.3% to RMB44.08 million, lifting the gross margin to 38.4% from 34.4%. Aesthetic medical services generated gross profit of RMB26.32 million (margin 33.6%), whereas the device segment delivered RMB17.76 million (margin 48.7%).

Operating expenses were mixed: selling and distribution cost rose to RMB22.37 million (+11.3%), reflecting stepped-up marketing, while administrative expenses fell to RMB14.40 million (-8.9%) thanks to facility consolidation. Finance costs declined to RMB0.99 million from RMB1.40 million.

Cash and bank balances stood at RMB48.67 million at period-end (31 December 2025: RMB57.79 million). Net current liabilities were narrowed to RMB0.71 million from RMB29.21 million. Interest-bearing bank borrowings increased to RMB35.00 million (31 December 2025: RMB18.00 million), all at fixed rates.

Capital expenditure reached RMB23.57 million, mainly for new equipment and facility upgrades. The company raised HKD19.0 million net via a rights issue in April 2024, of which HKD2.50 million remains unutilised and is earmarked for ongoing NMPA registration-related activities for new aesthetic medical devices.

Strategic initiatives include accelerating R&D of collagen-based injectables, expanding Mainland China’s non-surgical aesthetic services, and scaling the recently launched Hong Kong clinic, which generated RMB8.50 million revenue in its first half-year of operation.

No interim dividend was declared. The board affirmed that current cash, anticipated operating cash flows, and available facilities provide sufficient liquidity for ongoing operations.